GSK presents promising new data for bepirovirsen, an investigational treatment for chronic hepatitis B

GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries


GSK to present new data from the B-Clear phase IIb trial for bepirovirsen in chronic hepatitis B at the International Liver Congress 2022


GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults


GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older


Update: Proposed demerger of the Consumer Healthcare business from GSK to form Haleon